"I am pleased to announce further progress being made by our partner BIO. Following the progress made by their pathfinder clinical laboratory, BIO's strategy has developed to more appropriately reflect the large market opportunity they are seeing for the Company's CIZ1B biomarker test in North America. They have therefore realigned their accreditation and market launch plans to the new multi-site clinical laboratory to enable a much wider co-ordinated and comprehensive campaign to roll out the CIZ1B biomarker test in North America, to help detect early-stage lung cancer. This new agreement with a significantly larger multi-site clinical laboratory demonstrates how BIO intends to scale its operations throughout the USA.
"BIO's commitment to our strong partnership is also evident by the receipt of an early advance royalty payment which means the Company has now received US$525,000. We have since agreed to a more balanced payment schedule through to the end of 2026 which will see the remainder of the advance royalty fees being received by Cizzle Biotechnology earlier.
"I look forward to announcing further updates on BIO's commercial progress in North America and the Company's strategy to make its CIZ1B biomarker test available globally in due course."
This was 10 months ago, what exactly is his idea of "near future"?
"I am delighted to announce the positive progress being made by our partners Cizzle Bio who have appointed the first of their COLA and CLIA accredited clinical diagnostics laboratories to bring our CIZ1B Biomarker test for early-stage lung cancer to market. In the short time since we began our exclusive licensing partnership with Cizzle Bio, they have initiated multiple ongoing partnerships with several National Cancer Institute (NCI) designated cancer centres throughout the United States, with the goal of enhancing early detection capabilities for lung cancer. They have strengthened their leadership team with industry and clinical expertise and in creating the launchpad for our CIZ1B biomarker test. In collaboration with Cizzle Bio we continue to work closely with iGenomeDX's exceptional leadership and technical team to ensure a seamless transition of technology into the clinic. We look forward to sharing updates on their first commercially available tests in the near future."
They bang on about what they've done this year in terms of progression, yet, all their deadlines have been well n truly missed, and most notably they've once again delivered zero value to shareholders.
Lol, JHFH is a company spin doctor, nothing more nothing less, why do some of you actually believe he's a hemo guru?? pmsl the utter naievity deserves a hammering imo.
nice to see it hovering around up here, hopefully ready for a next leg up? and great to see it holding so well today given the wider markets **** show.